抗甲状腺髓样癌新药卡博替尼  

Pharmacological and clinical studies of cabozantinib

作　　者：郑希元[1] 姜汉杰[1] 蒲小平[1] 

机构地区：[1]北京大学药学院分子与细胞药理学系,北京100191

出　　处：《中国新药杂志》2013年第17期1990-1993,共4页Chinese Journal of New Drugs

摘　　要：卡博替尼作为一种抑制MET、血管内皮生长因子受体2(VEGFR2)和RET的酪氨酸激酶抑制剂,可阻断肿瘤细胞发生和发展,临床上用于进展性、转移性甲状腺髓样癌(MTC)患者的治疗。文中对卡博替尼的作用机制、药动学、药物相互作用、临床评价和安全性等进行综述。Cabozantinib,a new drug for medullary thyroid cancer treatment,is a potent inhibitor of MET,RET,and vascular endothelial factor receptor 2（VEGFR2） as well as other tyrosine kinases that have been implicated in tumor development and progression.The mechanism,pharmacokinetics,drug interaction,clinical evaluation,and safety of cabozantinib were reviewed.

关 键 词：卡博替尼 甲状腺髓样癌 酪氨酸激酶抑制剂 

分 类 号：R979.1[医药卫生—药品]